Want to see KR:033270 full AI Analyst Report?
Top Page
KOREA UNITED PHARM, INC.
(033270)
Select Model
Select Model
Rating:71Outperform
Price Target:
₩17,978.00
Action:N/A
Date:10/28/26
The score is primarily supported by strong financial strength (very low leverage, improved profitability, and solid operating cash flow coverage) and compelling valuation (very low P/E and a ~3.75% dividend yield). These positives are meaningfully offset by weak technicals, with the stock trading below major moving averages and showing negative momentum signals.
Positive Factors
Very low leverage
Very low leverage gives the company substantial financial resilience and flexibility. Limited debt obligations reduce pressure on earnings and cash flow, while preserving capacity to fund pharmaceutical development, sustain operations, and respond to changing market conditions over the next several quarters.
Negative Factors
Free cash flow inconsistency
Only about half of reported earnings converted into free cash flow in the TTM period, and prior results included notably weak free cash flow. This inconsistency can limit dependable funding for development, expansion, and distributions, making the company’s cash-generation profile less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Very low leverage gives the company substantial financial resilience and flexibility. Limited debt obligations reduce pressure on earnings and cash flow, while preserving capacity to fund pharmaceutical development, sustain operations, and respond to changing market conditions over the next several quarters.
Read all positive factors
KOREA UNITED PHARM, INC. (033270) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩243.17B
Dividend Yield3.64%
Average Volume (3M)29.74K
Price to Earnings (P/E)3.4
Beta (1Y)0.05
Revenue Growth4.13%
EPS Growth116.32%
CountryKR
Employees936
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4922.11
Shares Outstanding15,910,775
10 Day Avg. Volume38,256
30 Day Avg. Volume29,744
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.69
Price to Sales (P/S)1.08
P/FCF Ratio11.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2,966
Revenue Forecast (FY)₩303.50B
KOREA UNITED PHARM, INC. Business Overview & Revenue Model
Company Description
Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fie...
KOREA UNITED PHARM, INC. Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 298.08B | 288.76B | 288.71B | 278.94B | 262.52B | 221.04B |
| Gross Profit | 175.93B | 175.41B | 163.97B | 158.98B | 145.29B | 122.66B |
| EBITDA | 65.18B | 60.47B | 57.84B | 70.78B | 62.05B | 46.90B |
| Net Income | 76.16B | 38.31B | 32.45B | 48.26B | 45.28B | 28.65B |
Balance Sheet | ||||||
| Total Assets | 570.76B | 519.49B | 473.93B | 468.86B | 417.89B | 380.03B |
| Cash, Cash Equivalents and Short-Term Investments | 178.56B | 157.07B | 132.32B | 151.05B | 142.63B | 123.20B |
| Total Debt | 14.86B | 14.02B | 15.65B | 40.34B | 30.30B | 32.99B |
| Total Liabilities | 73.13B | 64.82B | 67.72B | 90.18B | 80.03B | 79.32B |
| Stockholders Equity | 497.12B | 454.63B | 406.21B | 378.68B | 337.86B | 300.71B |
Cash Flow | ||||||
| Free Cash Flow | 41.32B | 27.70B | 5.57B | 19.34B | 39.57B | 31.30B |
| Operating Cash Flow | 83.93B | 51.14B | 26.79B | 50.65B | 63.78B | 44.09B |
| Investing Cash Flow | -60.40B | -41.07B | 11.70B | -56.41B | -87.90B | -17.70B |
| Financing Cash Flow | -4.62B | -3.63B | -29.46B | 2.55B | -10.59B | -8.20B |
KOREA UNITED PHARM, INC. Technical Analysis
Negative
―
Price Trends
17817.80
Negative
17751.10
Negative
18703.60
Negative
Market Momentum
-296.74
Positive
37.32
Neutral
11.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:033270, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 17445.50, equal to the 50-day MA of 17817.80, and equal to the 200-day MA of 18703.60, indicating a bearish trend. The MACD of -296.74 indicates Positive momentum. The RSI at 37.32 is Neutral, neither overbought nor oversold. The STOCH value of 11.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:033270.
KOREA UNITED PHARM, INC. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₩271.92B | 3.23 | ― | 5.47% | 10.18% | 149.93% | |
71 Outperform | ₩243.17B | 3.39 | ― | 3.64% | 4.13% | 116.32% | |
66 Neutral | ₩261.13B | 37.56 | ― | 5.59% | -5.16% | -53.05% | |
58 Neutral | ₩198.48B | 5.07 | ― | 2.80% | 11.64% | -4.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:033270
KOREA UNITED PHARM, INC.
16,760.00
-1,539.97
-8.42%
KR:003120
ILSUNG IS CO., LTD.
21,450.00
-484.51
-2.21%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:008490
Suheung Co. Ltd.
17,850.00
-9,106.65
-33.78%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
705.94
12.46%
KR:096760
JW Holdings Corporation
3,930.00
841.00
27.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.